{"title": "Coenzima Q10 (PDQ\u00ae)", "author": null, "url": "https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq", "hostname": "cancer.gov", "description": "Resumen de informaci\u00f3n revisada por expertos sobre el uso de la coenzima Q10 como tratamiento para las personas con c\u00e1ncer.", "sitename": "Instituto Nacional del C\u00e1ncer", "date": "2015-03-26", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Coenzima Q10 (PDQ\u00ae)\u2013Versi\u00f3n para profesionales de salud\nAspectos generales\nEste sumario de informaci\u00f3n sobre el\n[c\u00e1ncer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) proporciona una visi\u00f3n general del uso de la [coenzima](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) Q10 para el tratamiento de esta enfermedad. En este sumario se incluyen los antecedentes de la investigaci\u00f3n sobre la coenzima Q10 , una revisi\u00f3n de [estudios de laboratorio](/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y datos sobre las investigaciones con seres humanos. Aunque se identificaron varias formas de origen natural de la coenzima Q, la Q10 es la forma predominante que se encuentra en los seres humanos y la mayor\u00eda de los mam\u00edferos; adem\u00e1s, es la forma m\u00e1s estudiada por su potencial [terap\u00e9utico](/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=Spanish&dictionary=Cancer.gov). Por lo tanto, ser\u00e1 la \u00fanica forma de coenzima Q que se trate en este sumario.\nEste sumario contiene la siguiente informaci\u00f3n clave:\n- La coenzima Q10 se elabora de forma natural en el cuerpo.\n- La coenzima Q10 ayuda a las\n[c\u00e9lulas](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)a producir energ\u00eda y act\u00faa como [antioxidante](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).\n- Se ha demostrado que la coenzima Q10 estimula el\n[sistema inmunitario](/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)y protege el coraz\u00f3n del da\u00f1o causado por ciertos f\u00e1rmacos [quimioterap\u00e9uticos](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).\n- Se han detectado concentraciones\n[sangu\u00edneas](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)bajas de coenzima Q10 en pacientes con algunos tipos de c\u00e1ncer.\n- No se conocen informes de\n[ensayos cl\u00ednicos aleatorizados](/Common/PopUps/popDefinition.aspx?id=45858&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)sobre la coenzima Q10 como tratamiento para el c\u00e1ncer que hayan sido publicados en una revista cient\u00edfica revisada por expertos.\n- La coenzima Q10 se comercializa en los Estados Unidos como\n[suplemento alimentario](/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).\nMuchos de los t\u00e9rminos m\u00e9dicos y cient\u00edficos en este sumario tienen un enlace al\n[Diccionario de c\u00e1ncer del NCI](https://www.cancer.gov/publications/dictionaries/cancer-terms/) la primera vez que se mencionan en cada secci\u00f3n. Este diccionario se orienta a personas sin conocimientos especializados. Al pulsar sobre un t\u00e9rmino con un enlace, aparece la definici\u00f3n en una ventana separada.\nLas referencias bibliogr\u00e1ficas citadas en los sumarios de informaci\u00f3n sobre el c\u00e1ncer del\n[PDQ](/Common/PopUps/popDefinition.aspx?id=44271&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) pueden tener enlaces a otros sitios de Internet gestionados por individuos u organizaciones con el prop\u00f3sito de comercializar o promover el uso de tratamientos o productos espec\u00edficos. Estas referencias bibliogr\u00e1ficas se ofrecen solo con fines informativos. Su inclusi\u00f3n no se debe interpretar como la aprobaci\u00f3n del contenido de las p\u00e1ginas de Internet ni de ning\u00fan tratamiento o producto por parte del Consejo editorial del PDQ sobre las terapias integrales, alternativas y complementarias, o del [Instituto Nacional del C\u00e1ncer](/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).\nInformaci\u00f3n general\nLa\n[coenzima](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) Q10 (tambi\u00e9n conocida como CoQ10, Q10, vitamina Q10, ubiquinona y ubidecarenona) es un tipo de benzoquinona sintetizado de forma natural por el cuerpo humano. La \"Q\" y el \"10\" en el nombre se refieren al grupo qu\u00edmico quinona y a las 10 subunidades de isoprenilo que forman parte de la estructura de este compuesto. El t\u00e9rmino \"coenzima\" denota que se trata de una [mol\u00e9cula](/Common/PopUps/popDefinition.aspx?id=45065&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) org\u00e1nica (contiene \u00e1tomos de carbono) no proteica necesaria para el buen funcionamiento de su pareja [proteica](/Common/PopUps/popDefinition.aspx?id=46092&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (una [enzima](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) o un complejo enzim\u00e1tico). Las [c\u00e9lulas](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) del cuerpo utilizan la coenzima Q10 en un proceso conocido de las siguientes formas:\nMediante este proceso, las mitocondrias producen energ\u00eda para la multiplicaci\u00f3n y el mantenimiento de las c\u00e9lulas.[\n[1](#cit/section_2.1)- [4](#cit/section_2.4)] Las c\u00e9lulas del cuerpo tambi\u00e9n utilizan la coenzima Q10 como un [antioxidante](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) [end\u00f3geno](/Common/PopUps/popDefinition.aspx?id=44026&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [1](#cit/section_2.1), [2](#cit/section_2.2), [4](#cit/section_2.4)- [8](#cit/section_2.8)] Un antioxidante es una sustancia que protege las c\u00e9lulas contra los [radicales libres](/Common/PopUps/popDefinition.aspx?id=44030&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), sustancias qu\u00edmicas muy reactivas que a menudo contienen \u00e1tomos de ox\u00edgeno capaces de da\u00f1ar componentes celulares importantes, como el [ADN](/Common/PopUps/popDefinition.aspx?id=44393&version=healthprofessional&language=Spanish&dictionary=genetic) y los [l\u00edpidos](/Common/PopUps/popDefinition.aspx?id=46068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov). Adem\u00e1s, la concentraci\u00f3n [plasm\u00e1tica](/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de la coenzima Q10 se ha utilizado en estudios como una forma de medir el [estr\u00e9s oxidativo](/Common/PopUps/popDefinition.aspx?id=44072&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [9](#cit/section_2.9), [10](#cit/section_2.10)]\nLa coenzima Q10 se encuentra en la mayor\u00eda de los\n[tejidos](/Common/PopUps/popDefinition.aspx?id=46683&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), pero las concentraciones m\u00e1s altas se observan en los siguientes \u00f3rganos:[ [11](#cit/section_2.11)]\nLa concentraci\u00f3n m\u00e1s baja se encuentra en los\n[pulmones](/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [11](#cit/section_2.11)] En los tejidos, la concentraci\u00f3n de este compuesto disminuye a medida que la gente envejece debido al aumento de la demanda, la disminuci\u00f3n de la producci\u00f3n [ [11](#cit/section_2.11)] o el consumo insuficiente de los precursores qu\u00edmicos necesarios para la s\u00edntesis.[ [12](#cit/section_2.12)] En los seres humanos, las concentraciones [sangu\u00edneas](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) normales de la coenzima Q10 se han definido de modo variable, con valores normales notificados que oscilan de 0,30 [\u00b5g](/Common/PopUps/popDefinition.aspx?id=306521&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)/ [ml](/Common/PopUps/popDefinition.aspx?id=44214&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) a 3,48 \u00b5g/ml.[ [2](#cit/section_2.2), [4](#cit/section_2.4), [13](#cit/section_2.13), [14](#cit/section_2.14)]\nDada la importancia de la coenzima Q10 para optimizar la producci\u00f3n de energ\u00eda celular, se ha explorado el uso de este compuesto en el tratamiento de otras enfermedades adem\u00e1s del\n[c\u00e1ncer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov). La mayor\u00eda de estas investigaciones se enfocaron en el uso de la coenzima Q10 como un tratamiento para la enfermedad [cardiovascular](/Common/PopUps/popDefinition.aspx?id=44005&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [2](#cit/section_2.2), [4](#cit/section_2.4), [15](#cit/section_2.15)] En pacientes de c\u00e1ncer, con el uso de la coenzima Q10 se han observado los siguientes efectos:\n- Protecci\u00f3n del coraz\u00f3n frente a la\n[cardiotoxicidad](/Common/PopUps/popDefinition.aspx?id=44004&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)inducida por [antraciclinas](/Common/PopUps/popDefinition.aspx?id=44916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)(las antraciclinas son una familia de f\u00e1rmacos [quimioterap\u00e9uticos](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), como la [doxorrubicina](/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), que a veces da\u00f1an el coraz\u00f3n).[ [3](#cit/section_2.3), [16](#cit/section_2.16)- [18](#cit/section_2.18)]\n- Estimulaci\u00f3n del\n[sistema inmunitario](/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [19](#cit/section_2.19), [20](#cit/section_2.20)]\nLa estimulaci\u00f3n del sistema inmunitario por este compuesto tambi\u00e9n se observ\u00f3 en\n[estudios con animales](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y en seres humanos sin c\u00e1ncer.[ [21](#cit/section_2.21)- [27](#cit/section_2.27)] Debido en parte a su potencial [inmunoestimulante](/Common/PopUps/popDefinition.aspx?id=285968&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), la coenzima Q10 se ha utilizado como [terapia adyuvante](/Common/PopUps/popDefinition.aspx?id=45587&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en pacientes con diversos tipos de c\u00e1ncer.[ [17](#cit/section_2.17), [20](#cit/section_2.20), [28](#cit/section_2.28)- [33](#cit/section_2.33)]\nAunque es posible que la coenzima Q10 act\u00fae de modo indirecto contra el c\u00e1ncer por sus efectos en el sistema inmunitario, hay evidencia que indica que los\n[an\u00e1logos](/Common/PopUps/popDefinition.aspx?id=44919&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de este compuesto pueden suprimir de manera directa el crecimiento del c\u00e1ncer. Se ha observado que los an\u00e1logos de la coenzima Q10 inhiben la [proliferaci\u00f3n](/Common/PopUps/popDefinition.aspx?id=44572&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de c\u00e9lulas cancerosas [in vitro](/Common/PopUps/popDefinition.aspx?id=45733&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y la multiplicaci\u00f3n de c\u00e9lulas cancerosas [trasplantadas](/Common/PopUps/popDefinition.aspx?id=46631&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en ratas y ratones.[ [12](#cit/section_2.12), [34](#cit/section_2.34)] En vista de estos hallazgos, se plante\u00f3 que los an\u00e1logos de la coenzima Q10 tal vez act\u00faen como [antimetabolitos](/Common/PopUps/popDefinition.aspx?id=45152&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) que interrumpen las [reacciones bioqu\u00edmicas](/Common/PopUps/popDefinition.aspx?id=44124&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) normales necesarias para la multiplicaci\u00f3n o la supervivencia de las c\u00e9lulas; por lo tanto, quiz\u00e1s sean \u00fatiles como [medicamentos quimioterap\u00e9uticos](/Common/PopUps/popDefinition.aspx?id=44009&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [12](#cit/section_2.12), [34](#cit/section_2.34)]\nVarias compa\u00f1\u00edas distribuyen la coenzima Q10 como\n[suplemento alimentario](/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=Spanish&dictionary=Cancer.gov). En los Estados Unidos, los suplementos alimentarios se reglamentan como alimentos, no como medicamentos. Por lo tanto, no se exige la evaluaci\u00f3n y la aprobaci\u00f3n de la [Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos](/Common/PopUps/popDefinition.aspx?id=454785&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (FDA) antes de la comercializaci\u00f3n, a menos que se presente informaci\u00f3n espec\u00edfica sobre su utilidad para [prevenir](/Common/PopUps/popDefinition.aspx?id=439419&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) o tratar una enfermedad. No obstante, la FDA puede retirar del mercado los suplementos alimentarios que considere peligrosos. Debido a que los suplementos alimentarios no se someten a una revisi\u00f3n formal para uniformar la fabricaci\u00f3n de los mismos, los ingredientes var\u00edan mucho entre cada lote y no hay garant\u00edas en cuanto a la presencia de los ingredientes que constan en las etiquetas del producto (o de que se encuentren en las cantidades especificadas). La FDA no ha aprobado la coenzima Q10 para el tratamiento del c\u00e1ncer ni de ninguna otra afecci\u00f3n.\nPara llevar a cabo la investigaci\u00f3n\n[cl\u00ednica](/Common/PopUps/popDefinition.aspx?id=44168&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de medicamentos en los Estados Unidos, los investigadores deben presentar una solicitud de un nuevo medicamento (IND) a la FDA. El proceso de solicitud de una IND es estrictamente confidencial y la informaci\u00f3n de la IND solo la pueden revelar los solicitantes. Hasta la fecha, ning\u00fan investigador anunci\u00f3 haber solicitado una IND para estudiar la coenzima Q10 como un tratamiento del c\u00e1ncer.\nEn estudios con animales, la coenzima Q10 se ha administrado por\n[inyecci\u00f3n](/Common/PopUps/popDefinition.aspx?id=44678&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) ( [intravenosa](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [intraperitoneal](/Common/PopUps/popDefinition.aspx?id=46339&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [intramuscular](/Common/PopUps/popDefinition.aspx?id=44048&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) o [subcut\u00e1nea](/Common/PopUps/popDefinition.aspx?id=45914&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)). Si bien en los seres humanos se suele tomar por v\u00eda [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en forma de pastillas (perlas de gel o [c\u00e1psulas](/Common/PopUps/popDefinition.aspx?id=455334&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)), tambi\u00e9n se administra por [infusiones](/Common/PopUps/popDefinition.aspx?id=45738&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) intravenosas.[ [4](#cit/section_2.4)] La coenzima Q10 se absorbe mejor con grasa; por lo tanto, los preparados con l\u00edpidos se asimilan mejor que el compuesto purificado.[ [2](#cit/section_2.2), [4](#cit/section_2.4)] En estudios con seres humanos, las [dosis](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de suplementos y los esquemas de administraci\u00f3n var\u00edan, pero, por lo general, oscilan de 90 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)/d\u00eda a 390 mg/d\u00eda.\nBibliograf\u00eda\n- Crane FL, Sun IL, Sun EE: The essential functions of coenzyme Q. Clin Investig 71 (8 Suppl): S55-9, 1993.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241706&dopt=Abstract)\n- Pepping J: Coenzyme Q10. Am J Health Syst Pharm 56 (6): 519-21, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract)\n- Folkers K, Wolaniuk A: Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 11 (8): 539-45, 1985.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract)\n- Overvad K, Diamant B, Holm L, et al.: Coenzyme Q10 in health and disease. Eur J Clin Nutr 53 (10): 764-70, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract)\n- Beyer RE, Nordenbrand K, Ernster L: The role of coenzyme Q as a mitochondrial antioxidant: a short review. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 5. Elsevier Science Publishers B V (Biomedical Division), 1986, pp 17-24.\n- Gordon M: Dietary antioxidants in disease prevention. Nat Prod Rep 13 (4): 265-73, 1996.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8760864&dopt=Abstract)\n- Palazzoni G, Pucello D, Littarru GP, et al.: Coenzyme Q10 and colorectal neoplasms in aged patients. Rays 22 (1 Suppl): 73-6, 1997 Jan-Mar.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9250020&dopt=Abstract)\n- Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271 (1): 195-204, 1995.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7599208&dopt=Abstract)\n- Yamamoto Y, Yamashita S, Fujisawa A, et al.: Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 247 (1): 166-70, 1998.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9636673&dopt=Abstract)\n- Yamamoto Y, Yamashita S: Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med 18 (Suppl): S79-84, 1997.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9266509&dopt=Abstract)\n- Ernster L, Forsmark-Andr\u00e9e P: Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 71 (8 Suppl): S60-5, 1993.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241707&dopt=Abstract)\n- Folkers K: The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 4 (4): 19-22, 1974.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract)\n- Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract)\n- Jolliet P, Simon N, Barr\u00e9 J, et al.: Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 36 (9): 506-9, 1998.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9760013&dopt=Abstract)\n- Baggio E, Gandini R, Plancher AC, et al.: Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 15 (Suppl): s287-94, 1994.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752841&dopt=Abstract)\n- Cortes EP, Gupta M, Chou C, et al.: Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 62 (6): 887-91, 1978.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=667863&dopt=Abstract)\n- Folkers K, Brown R, Judy WV, et al.: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192 (1): 241-5, 1993.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract)\n- Iarussi D, Auricchio U, Agretto A, et al.: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 15 (Suppl): s207-12, 1994.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752832&dopt=Abstract)\n- Folkers K, Shizukuishi S, Takemura K, et al.: Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol 38 (2): 335-8, 1982.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7163631&dopt=Abstract)\n- Complementary treatments highlighted at recent meeting. Oncology (Huntingt) 13 (2): 166, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10079467&dopt=Abstract)\n- Bliznakov E, Casey A, Premuzic E: Coenzymes Q: stimulants of the phagocytic activity in rats and immune response in mice. Experientia 26 (9): 953-4, 1970.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5478631&dopt=Abstract)\n- Folkers K, Hanioka T, Xia LJ, et al.: Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 176 (2): 786-91, 1991.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1673841&dopt=Abstract)\n- Kawase I, Niitani H, Saijo N, et al.: Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice. Gann 69 (4): 493-7, 1978.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=101414&dopt=Abstract)\n- Bliznakov EG: Effect of stimulation of the host defense system by coenzyme Q 10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A 70 (2): 390-4, 1973.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract)\n- Bliznakov EG, Adler AD: Nonlinear response of the reticuloendothelial system upon stimulation. Pathol Microbiol (Basel) 38 (6): 393-410, 1972.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract)\n- Bliznakov EG: Coenzyme Q in experimental infections and neoplasia. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Elsevier/North-Holland Biomedical Press, 1977, pp 73-83.\n- Barbieri B, Lund B, Lundstr\u00f6m B, et al.: Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study. Biofactors 9 (2-4): 351-7, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416052&dopt=Abstract)\n- Lockwood K, Moesgaard S, Hanioka T, et al.: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15 (Suppl): s231-40, 1994.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract)\n- Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 199 (3): 1504-8, 1994.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7908519&dopt=Abstract)\n- Lockwood K, Moesgaard S, Yamamoto T, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212 (1): 172-7, 1995.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract)\n- Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224 (2): 358-61, 1996.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract)\n- Ren S, Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48: 147-71, 1997.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract)\n- Hodges S, Hertz N, Lockwood K, et al.: CoQ10: could it have a role in cancer management? Biofactors 9 (2-4): 365-70, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416054&dopt=Abstract)\n- Folkers K, Porter TH, Bertino JR, et al.: Inhibition of two human tumor cell lines by antimetabolites of coenzyme Q10. Res Commun Chem Pathol Pharmacol 19 (3): 485-90, 1978.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=653103&dopt=Abstract)\nAntecedentes\nLa\n[coenzima](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) Q10 se aisl\u00f3 por primera vez en 1957; su estructura qu\u00edmica (compuesto de benzoquinona) se determin\u00f3 en 1958.[ [1](#cit/section_3.1), [2](#cit/section_3.2)] El inter\u00e9s por la coenzima Q10 como sustancia [terap\u00e9utica](/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) para el [c\u00e1ncer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) comenz\u00f3 en 1961, cuando se observ\u00f3 una [deficiencia](/Common/PopUps/popDefinition.aspx?id=321364&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en la [sangre](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de pacientes oncol\u00f3gicos suecos y estadounidenses; en particular, en la sangre de pacientes con [c\u00e1ncer de mama](/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [2](#cit/section_3.2)- [4](#cit/section_3.4)] En un [estudio](/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) posterior, se observ\u00f3 una relaci\u00f3n [estad\u00edsticamente significativa](/Common/PopUps/popDefinition.aspx?id=44167&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) entre la deficiencia en la concentraci\u00f3n [plasm\u00e1tica](/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de la coenzima Q10y el [pron\u00f3stico](/Common/PopUps/popDefinition.aspx?id=45849&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) del c\u00e1ncer de mama.[ [5](#cit/section_3.5)] Se notificaron concentraciones sangu\u00edneas bajas de este compuesto en la sangre de pacientes con otras [neoplasias malignas](/Common/PopUps/popDefinition.aspx?id=45771&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) diferentes al c\u00e1ncer de mama, como [mieloma](/Common/PopUps/popDefinition.aspx?id=45795&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [linfoma](/Common/PopUps/popDefinition.aspx?id=45368&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y c\u00e1nceres de [pulm\u00f3n](/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [pr\u00f3stata](/Common/PopUps/popDefinition.aspx?id=46539&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [p\u00e1ncreas](/Common/PopUps/popDefinition.aspx?id=46254&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [colon](/Common/PopUps/popDefinition.aspx?id=46462&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [ri\u00f1\u00f3n](/Common/PopUps/popDefinition.aspx?id=46325&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y [cabeza y cuello](/Common/PopUps/popDefinition.aspx?id=257519&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [2](#cit/section_3.2), [6](#cit/section_3.6), [7](#cit/section_3.7)] Adem\u00e1s, se detectaron disminuciones en la concentraci\u00f3n de coenzima Q10 en [tejidos](/Common/PopUps/popDefinition.aspx?id=46683&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de neoplasias [malignas](/Common/PopUps/popDefinition.aspx?id=45772&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en seres humanos,[ [8](#cit/section_3.8)- [12](#cit/section_3.12)] pero tambi\u00e9n se notificaron aumentos de la concentraci\u00f3n.[ [8](#cit/section_3.8)]\nUna gran cantidad de datos de\n[laboratorio](/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y en [animales](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) sobre la coenzima Q10 se han acumulado desde 1962.[ [2](#cit/section_3.2)] La investigaci\u00f3n acerca de los mecanismos de producci\u00f3n de energ\u00eda celular en los que participa este compuesto recibi\u00f3 el Premio Nobel de Qu\u00edmica en 1978. En algunos de los datos acumulados, se observa que la coenzima Q10 estimula el [sistema inmunitario](/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de los animales, lo que conduce a una mayor concentraci\u00f3n de [anticuerpos](/Common/PopUps/popDefinition.aspx?id=44918&version=healthprofessional&language=Spanish&dictionary=Cancer.gov),[ [13](#cit/section_3.13)] mayor n\u00famero o actividad de [macr\u00f3fagos](/Common/PopUps/popDefinition.aspx?id=44054&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y [c\u00e9lulas T](/Common/PopUps/popDefinition.aspx?id=44928&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) ( [linfocitos](/Common/PopUps/popDefinition.aspx?id=45765&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) T),[ [13](#cit/section_3.13), [14](#cit/section_3.14)] adem\u00e1s de aumento en la resistencia a las [infecciones](/Common/PopUps/popDefinition.aspx?id=45364&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [15](#cit/section_3.15)- [17](#cit/section_3.17)] Tambi\u00e9n se notific\u00f3 que la coenzima Q10 aumenta las concentraciones de anticuerpos IgG ( [inmunoglobulina](/Common/PopUps/popDefinition.aspx?id=45725&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) G) y el cociente CD4/CD8 en las c\u00e9lulas T de seres humanos.[ [18](#cit/section_3.18)- [20](#cit/section_3.20)] CD4 y CD8 son [prote\u00ednas](/Common/PopUps/popDefinition.aspx?id=46092&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) que se encuentran en la superficie de las c\u00e9lulas T; CD4 y CD8 identifican las [c\u00e9lulas T auxiliares](/Common/PopUps/popDefinition.aspx?id=44594&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y las [c\u00e9lulas T citot\u00f3xicas](/Common/PopUps/popDefinition.aspx?id=45664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), respectivamente. Se notificaron disminuciones del cociente CD4/CD8 en las c\u00e9lulas T de pacientes oncol\u00f3gicos.[ [21](#cit/section_3.21), [22](#cit/section_3.22)] En investigaciones posteriores, se definieron las propiedades [antioxidantes](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de la coenzima Q10.[ [23](#cit/section_3.23)- [27](#cit/section_3.27)]\nLos mecanismos de acci\u00f3n propuestos para la coenzima Q10 que son importantes para el c\u00e1ncer incluyen su funci\u00f3n esencial en la producci\u00f3n de energ\u00eda celular y la estimulaci\u00f3n del sistema inmunitario (que quiz\u00e1s est\u00e9n relacionados entre s\u00ed), as\u00ed como su funci\u00f3n antioxidante. La coenzima Q10 es fundamental para la producci\u00f3n de energ\u00eda\n[aer\u00f3bica](/Common/PopUps/popDefinition.aspx?id=43991&version=healthprofessional&language=Spanish&dictionary=Cancer.gov),[ [1](#cit/section_3.1), [25](#cit/section_3.25), [28](#cit/section_3.28)] y se indic\u00f3 que el aumento de la energ\u00eda celular conduce a un incremento de la s\u00edntesis de anticuerpos en las [c\u00e9lulas B](/Common/PopUps/popDefinition.aspx?id=45611&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) ( [linfocitos B](/Common/PopUps/popDefinition.aspx?id=44953&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)).[ [6](#cit/section_3.6), [18](#cit/section_3.18)] Como se se\u00f1alo antes (secci\u00f3n [Informaci\u00f3n General](/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq#_5)), la coenzima Q10 tambi\u00e9n se comporta como un antioxidante.[ [1](#cit/section_3.1), [25](#cit/section_3.25)- [27](#cit/section_3.27), [29](#cit/section_3.29)- [32](#cit/section_3.32)] Se cree que, mediante esta funci\u00f3n, la coenzima Q10 estabiliza las membranas celulares (estructuras [lip\u00eddicas](/Common/PopUps/popDefinition.aspx?id=46068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) esenciales para el mantenimiento de la integridad celular) y previene el da\u00f1o que producen los [radicales libres](/Common/PopUps/popDefinition.aspx?id=44030&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) a otros componentes celulares importantes.[ [1](#cit/section_3.1), [25](#cit/section_3.25), [27](#cit/section_3.27), [32](#cit/section_3.32)] El da\u00f1o al [ADN](/Common/PopUps/popDefinition.aspx?id=44393&version=healthprofessional&language=Spanish&dictionary=genetic) (y quiz\u00e1s a otras [mol\u00e9culas](/Common/PopUps/popDefinition.aspx?id=45065&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) celulares) causado por los radicales libres es posible que sea un factor en la formaci\u00f3n del c\u00e1ncer.[ [11](#cit/section_3.11), [23](#cit/section_3.23), [30](#cit/section_3.30), [33](#cit/section_3.33)- [36](#cit/section_3.36)]\nBibliograf\u00eda\n- Pepping J: Coenzyme Q10. Am J Health Syst Pharm 56 (6): 519-21, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract)\n- Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract)\n- Lockwood K, Moesgaard S, Yamamoto T, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212 (1): 172-7, 1995.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract)\n- Ren S, Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48: 147-71, 1997.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract)\n- Jolliet P, Simon N, Barr\u00e9 J, et al.: Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 36 (9): 506-9, 1998.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9760013&dopt=Abstract)\n- Folkers K: The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 4 (4): 19-22, 1974.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract)\n- Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224 (2): 358-61, 1996.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract)\n- Chipperfield B: Ubiquinone concentrations in some tumour-bearing tissues. Ubiquinone concentrations in tumours and some normal tissues in man. Nature 209 (29): 1207-8, 1966.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5225398&dopt=Abstract)\n- Eggens I, Elmberger PG, L\u00f6w P: Polyisoprenoid, cholesterol and ubiquinone levels in human hepatocellular carcinomas. Br J Exp Pathol 70 (1): 83-92, 1989.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2538136&dopt=Abstract)\n- Mano T, Iwase K, Hayashi R, et al.: Vitamin E and coenzyme Q concentrations in the thyroid tissues of patients with various thyroid disorders. Am J Med Sci 315 (4): 230-2, 1998.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9537635&dopt=Abstract)\n- Picardo M, Grammatico P, Roccella F, et al.: Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Invest Dermatol 107 (3): 322-6, 1996.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8751964&dopt=Abstract)\n- Portakal O, Ozkaya O, Erden Inal M, et al.: Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 33 (4): 279-84, 2000.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10936586&dopt=Abstract)\n- Bliznakov E, Casey A, Premuzic E: Coenzymes Q: stimulants of the phagocytic activity in rats and immune response in mice. Experientia 26 (9): 953-4, 1970.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5478631&dopt=Abstract)\n- Kawase I, Niitani H, Saijo N, et al.: Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice. Gann 69 (4): 493-7, 1978.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=101414&dopt=Abstract)\n- Bliznakov EG: Effect of stimulation of the host defense system by coenzyme Q 10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A 70 (2): 390-4, 1973.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract)\n- Bliznakov EG, Adler AD: Nonlinear response of the reticuloendothelial system upon stimulation. Pathol Microbiol (Basel) 38 (6): 393-410, 1972.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract)\n- Bliznakov EG: Coenzyme Q in experimental infections and neoplasia. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Elsevier/North-Holland Biomedical Press, 1977, pp 73-83.\n- Folkers K, Shizukuishi S, Takemura K, et al.: Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol 38 (2): 335-8, 1982.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7163631&dopt=Abstract)\n- Folkers K, Hanioka T, Xia LJ, et al.: Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 176 (2): 786-91, 1991.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1673841&dopt=Abstract)\n- Barbieri B, Lund B, Lundstr\u00f6m B, et al.: Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study. Biofactors 9 (2-4): 351-7, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416052&dopt=Abstract)\n- Shaw M, Ray P, Rubenstein M, et al.: Lymphocyte subsets in urologic cancer patients. Urol Res 15 (3): 181-5, 1987.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2957843&dopt=Abstract)\n- Tsuyuguchi I, Shiratsuchi H, Fukuoka M: T-lymphocyte subsets in primary lung cancer. Jpn J Clin Oncol 17 (1): 13-7, 1987.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3494139&dopt=Abstract)\n- Yamamoto Y, Yamashita S, Fujisawa A, et al.: Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 247 (1): 166-70, 1998.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9636673&dopt=Abstract)\n- Yamamoto Y, Yamashita S: Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med 18 (Suppl): S79-84, 1997.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9266509&dopt=Abstract)\n- Crane FL, Sun IL, Sun EE: The essential functions of coenzyme Q. Clin Investig 71 (8 Suppl): S55-9, 1993.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241706&dopt=Abstract)\n- Overvad K, Diamant B, Holm L, et al.: Coenzyme Q10 in health and disease. Eur J Clin Nutr 53 (10): 764-70, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract)\n- Ernster L, Forsmark-Andr\u00e9e P: Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 71 (8 Suppl): S60-5, 1993.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241707&dopt=Abstract)\n- Folkers K, Wolaniuk A: Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 11 (8): 539-45, 1985.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract)\n- Beyer RE, Nordenbrand K, Ernster L: The role of coenzyme Q as a mitochondrial antioxidant: a short review. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 5. Elsevier Science Publishers B V (Biomedical Division), 1986, pp 17-24.\n- Gordon M: Dietary antioxidants in disease prevention. Nat Prod Rep 13 (4): 265-73, 1996.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8760864&dopt=Abstract)\n- Palazzoni G, Pucello D, Littarru GP, et al.: Coenzyme Q10 and colorectal neoplasms in aged patients. Rays 22 (1 Suppl): 73-6, 1997 Jan-Mar.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9250020&dopt=Abstract)\n- Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271 (1): 195-204, 1995.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7599208&dopt=Abstract)\n- Aust AE, Eveleigh JF: Mechanisms of DNA oxidation. Proc Soc Exp Biol Med 222 (3): 246-52, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10601883&dopt=Abstract)\n- Halliwell B: Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res 443 (1-2): 37-52, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10415430&dopt=Abstract)\n- Burcham PC: Internal hazards: baseline DNA damage by endogenous products of normal metabolism. Mutat Res 443 (1-2): 11-36, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10415429&dopt=Abstract)\n- Dreher D, Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer 32A (1): 30-8, 1996.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8695238&dopt=Abstract)\nEstudios precl\u00ednicos de laboratorio o con animales\nEl trabajo de\n[laboratorio](/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) sobre la [coenzima](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) Q10 se ha centrado, sobre todo, en su estructura y su funci\u00f3n en la [respiraci\u00f3n celular](/Common/PopUps/popDefinition.aspx?id=44008&version=healthprofessional&language=Spanish&dictionary=Cancer.gov). En los estudios con [animales](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) se demostr\u00f3 que la coenzima Q10 estimula el [sistema inmunitario](/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=Spanish&dictionary=Cancer.gov); los animales tratados presentaron mayor resistencia a las [infecciones](/Common/PopUps/popDefinition.aspx?id=45364&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) [protozoarias](/Common/PopUps/popDefinition.aspx?id=44080&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) [ [1](#cit/section_4.1), [2](#cit/section_4.2)] y a las [neoplasias](/Common/PopUps/popDefinition.aspx?id=45801&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) inducidas por [virus](/Common/PopUps/popDefinition.aspx?id=44629&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) o sustancias qu\u00edmicas.[ [1](#cit/section_4.1)- [4](#cit/section_4.4)] En los primeros estudios sobre la coenzima Q10 se observ\u00f3 un aumento de la [hematopoyesis](/Common/PopUps/popDefinition.aspx?id=44035&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (formaci\u00f3n de nuevos gl\u00f3bulos [sangu\u00edneos](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)) en monos,[ [4](#cit/section_4.4), [5](#cit/section_4.5)] conejos,[ [6](#cit/section_4.6)] y aves de corral.[ [5](#cit/section_4.5)] La coenzima Q10 demostr\u00f3 un efecto protector sobre el m\u00fasculo card\u00edaco de ratones, ratas y conejos que recibieron el medicamento contra el c\u00e1ncer [doxorrubicina](/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), un tipo de [antraciclina](/Common/PopUps/popDefinition.aspx?id=44916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [7](#cit/section_4.7)- [12](#cit/section_4.12)] Si bien en otro estudio se confirm\u00f3 este efecto protector con la administraci\u00f3n de doxorrubicina [intraperitoneal](/Common/PopUps/popDefinition.aspx?id=46339&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en ratones, no se demostr\u00f3 un efecto protector cuando la antraciclina se administr\u00f3 por v\u00eda [intravenosa](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), que es la v\u00eda de administraci\u00f3n en seres humanos.[ [13](#cit/section_4.13)]\nLos investigadores de un estudio emitieron una advertencia cuando descubrieron que la administraci\u00f3n conjunta de coenzima Q10 y\n[radioterapia](/Common/PopUps/popDefinition.aspx?id=44971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) disminuye la eficacia de esta \u00faltima.[ [14](#cit/section_4.14)] En este estudio, los ratones inoculados con c\u00e9lulas humanas de [c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as](/Common/PopUps/popDefinition.aspx?id=45327&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (estudio de [xenoinjerto](/Common/PopUps/popDefinition.aspx?id=44095&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)), que despu\u00e9s recibieron la coenzima Q10 y una [dosis](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) \u00fanica de radioterapia, tuvieron una inhibici\u00f3n del crecimiento [tumoral](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) mucho menor que los ratones del [grupo de control](/Common/PopUps/popDefinition.aspx?id=44149&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) tratados con radioterapia sola. Dado que la radiaci\u00f3n conduce a la producci\u00f3n de [radicales libres](/Common/PopUps/popDefinition.aspx?id=44030&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y que los [antioxidantes](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) protegen contra el da\u00f1o de los radicales libres, el efecto en este estudio quiz\u00e1s se explique por la acci\u00f3n antioxidante de la coenzima Q10 . Como se se\u00f1al\u00f3 antes, en estudios de laboratorio y con animales se obtuvo cierta evidencia de que los [an\u00e1logos](/Common/PopUps/popDefinition.aspx?id=44919&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de la coenzima Q10 quiz\u00e1s tengan actividad anticancer\u00edgena directa.[ [15](#cit/section_4.15), [16](#cit/section_4.16)] Consultar la secci\u00f3n [Informaci\u00f3n General](/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq#_5).\nBibliograf\u00eda\n- Bliznakov EG, Adler AD: Nonlinear response of the reticuloendothelial system upon stimulation. Pathol Microbiol (Basel) 38 (6): 393-410, 1972.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract)\n- Bliznakov EG: Coenzyme Q in experimental infections and neoplasia. In: Folkers K, Yamamura Y, eds.: Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Elsevier/North-Holland Biomedical Press, 1977, pp 73-83.\n- Bliznakov EG: Effect of stimulation of the host defense system by coenzyme Q 10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A 70 (2): 390-4, 1973.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract)\n- Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract)\n- Folkers K, Brown R, Judy WV, et al.: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192 (1): 241-5, 1993.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract)\n- Ludwig FC, Elashoff RM, Smith JL, et al.: Response of the bone marrow of the vitamin E-deficient rabbit to coenzyme Q and vitamin E. Scand J Haematol 4 (4): 292-300, 1967.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6078061&dopt=Abstract)\n- Choe JY, Combs AB, Folkers K: Prevention by coenzyme Q10 of the electrocardiographic changes induced by adriamycin in rats. Res Commun Chem Pathol Pharmacol 23 (1): 199-202, 1979.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=441512&dopt=Abstract)\n- Combs AB, Choe JY, Truong DH, et al.: Reduction by coenzyme Q10 of the acute toxicity of adriamycin in mice. Res Commun Chem Pathol Pharmacol 18 (3): 565-8, 1977.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=928953&dopt=Abstract)\n- Folkers K, Choe JY, Combs AB: Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat. Proc Natl Acad Sci U S A 75 (10): 5178-80, 1978.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=283424&dopt=Abstract)\n- Lubawy WC, Dallam RA, Hurley LH: Protection against anthramycin-induced toxicity in mice by coenzyme Q10. J Natl Cancer Inst 64 (1): 105-9, 1980.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6928034&dopt=Abstract)\n- Shinozawa S, Gomita Y, Araki Y: Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharm Bull 16 (11): 1114-7, 1993.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8312867&dopt=Abstract)\n- Usui T, Ishikura H, Izumi Y, et al.: Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q10. Toxicol Lett 12 (1): 75-82, 1982.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7112605&dopt=Abstract)\n- Shaeffer J, El-Mahdi AM, Nichols RK: Coenzyme Q10 and adriamycin toxicity in mice. Res Commun Chem Pathol Pharmacol 29 (2): 309-15, 1980.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7414051&dopt=Abstract)\n- Lund EL, Quistorff B, Spang-Thomsen M, et al.: Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol (Praha) 43 (5): 505-6, 1998.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9821311&dopt=Abstract)\n- Folkers K: The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 4 (4): 19-22, 1974.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract)\n- Folkers K, Porter TH, Bertino JR, et al.: Inhibition of two human tumor cell lines by antimetabolites of coenzyme Q10. Res Commun Chem Pathol Pharmacol 19 (3): 485-90, 1978.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=653103&dopt=Abstract)\nEstudios cl\u00ednicos con seres humanos\nLos\n[estudios cl\u00ednicos](/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) sobre el uso de la coenzima Q10 para la prevenci\u00f3n y el control de los [efectos secundarios](/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) del tratamiento del [c\u00e1ncer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), o como sustancia terap\u00e9utica para el c\u00e1ncer, son muy escasos. Es importante destacar, que en los [ensayos cl\u00ednicos](/Common/PopUps/popDefinition.aspx?id=45961&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) que estudian el uso de la coenzima Q10 en la prevenci\u00f3n de los efectos t\u00f3xicos del tratamiento oncol\u00f3gico, no se realiz\u00f3 un seguimiento a largo plazo para valorar los desenlaces de los pacientes y determinar si la coenzima Q10 disminuye la [eficacia](/Common/PopUps/popDefinition.aspx?id=346517&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) del tratamientos (por ejemplo, [quimioterapia](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y [radioterapia](/Common/PopUps/popDefinition.aspx?id=44971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)). En un [estudio de observaci\u00f3n](/Common/PopUps/popDefinition.aspx?id=286105&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) con 1134 pacientes de [c\u00e1ncer de mama](/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) inscritos en un ensayo cl\u00ednico multinstitucional del [Instituto Nacional del C\u00e1ncer](/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) ( [SWOG S0221](/clinicaltrials/NCT00070564)) se indic\u00f3 que el uso de suplementos [antioxidantes](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), como la coenzima Q10, antes del tratamiento del c\u00e1ncer y durante el mismo, quiz\u00e1s se relacione con tasas superiores de [recidiva](/Common/PopUps/popDefinition.aspx?id=45861&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y menor supervivencia.[ [1](#cit/section_5.1)]\nTratamiento de los s\u00edntomas y los efectos secundarios\nToxicidad card\u00edaca\nEn vista de los resultados prometedores de los\n[estudios con animales](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), la coenzima Q10 se prob\u00f3 como protector contra la toxicidad [card\u00edaca](/Common/PopUps/popDefinition.aspx?id=45634&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) observada en pacientes de c\u00e1ncer tratados con la [antraciclina](/Common/PopUps/popDefinition.aspx?id=44916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) [doxorrubicina](/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=Spanish&dictionary=Cancer.gov). Se postul\u00f3 que la doxorrubicina interfiere con las [reacciones bioqu\u00edmicas](/Common/PopUps/popDefinition.aspx?id=44124&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) productoras de energ\u00eda donde participa la coenzima Q10 en las [mitocondrias](/Common/PopUps/popDefinition.aspx?id=44060&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) del miocardio y que esta interferencia se supera al a\u00f1adir la coenzima Q10 como un [suplemento](/Common/PopUps/popDefinition.aspx?id=45916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [2](#cit/section_5.2)- [4](#cit/section_5.4)] En los estudios con adultos y ni\u00f1os, incluso en el [ensayo aleatorizado](/Common/PopUps/popDefinition.aspx?id=45858&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) que se mencion\u00f3 antes, se confirm\u00f3 la disminuci\u00f3n de la toxicidad card\u00edaca observada en los estudios con animales.[ [2](#cit/section_5.2), [5](#cit/section_5.5)- [7](#cit/section_5.7)] En un ensayo aleatorizado [ [7](#cit/section_5.7)] con 20 pacientes se evalu\u00f3 la capacidad de la coenzima Q10 para reducir la [cardiotoxicidad](/Common/PopUps/popDefinition.aspx?id=44004&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) causada por las antraciclinas.\nFatiga\nEn dos\n[ensayos controlados](/Common/PopUps/popDefinition.aspx?id=44014&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) aleatorizados se analiz\u00f3 el potencial de los suplementos de coenzima Q10para prevenir y tratar la [fatiga](/Common/PopUps/popDefinition.aspx?id=321374&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en pacientes que recib\u00edan tratamiento oncol\u00f3gico. En un ensayo aleatorizado [controlado con placebo](/Common/PopUps/popDefinition.aspx?id=44840&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) con 236 pacientes de c\u00e1ncer de mama que recibieron [quimioterapia adyuvante](/Common/PopUps/popDefinition.aspx?id=45587&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) con radioterapia o sin esta se concluy\u00f3 que la coenzima Q10 administrada en una [dosis](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) diaria de 300 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en combinaci\u00f3n con 300 [UI](/Common/PopUps/popDefinition.aspx?id=44764&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de [vitamina E](/Common/PopUps/popDefinition.aspx?id=45023&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), dividida en 3 dosis, no impidi\u00f3 el empeoramiento de los valores medios de fatiga o de [calidad de vida](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) inducido por el tratamiento despu\u00e9s de 24 semanas de administraci\u00f3n de suplementos.[ [8](#cit/section_5.8)] En otro ensayo m\u00e1s reducido (N = 59) se [administr\u00f3](/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) una dosis diaria de un suplemento diferente que conten\u00eda coenzima Q10 (30 mg), [amino\u00e1cidos](/Common/PopUps/popDefinition.aspx?id=446104&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de cadena ramificada (2500 mg) y [L-carnitina](/Common/PopUps/popDefinition.aspx?id=321377&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (50 mg). Durante los 21 d\u00edas del ensayo, todos los pacientes recibieron quimioterapia adyuvante y ninguno de ellos recibi\u00f3 radioterapia. En los resultados de este ensayo tampoco se demostr\u00f3 una diferencia significativa en los valores medios de fatiga entre el grupo de tratamiento y el [grupo de control](/Common/PopUps/popDefinition.aspx?id=44149&version=healthprofessional&language=Spanish&dictionary=Cancer.gov); sin embargo, se observ\u00f3 un beneficio [estad\u00edsticamente significativo](/Common/PopUps/popDefinition.aspx?id=44167&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en el [criterio principal de valoraci\u00f3n](/Common/PopUps/popDefinition.aspx?id=44163&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (valor m\u00e1ximo de fatiga en las \u00faltimas 24 horas) del estudio.[ [9](#cit/section_5.9)]\nTratamiento del c\u00e1ncer\nLa administraci\u00f3n de la\n[coenzima](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) Q10 para el tratamiento del c\u00e1ncer en seres humanos se ha investigado solo de manera limitada. En vista de que se observ\u00f3 que las concentraciones [sangu\u00edneas](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de la coenzima Q10 a menudo son bajas en los pacientes de c\u00e1ncer,[ [10](#cit/section_5.10)- [14](#cit/section_5.14)] se prob\u00f3 la administraci\u00f3n de suplementos de este [compuesto](/Common/PopUps/popDefinition.aspx?id=422394&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en pacientes sometidos a [tratamiento convencional](/Common/PopUps/popDefinition.aspx?id=44950&version=healthprofessional&language=Spanish&dictionary=Cancer.gov). En un estudio cl\u00ednico [sin enmascaramiento](/Common/PopUps/popDefinition.aspx?id=44066&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), abierto y no controlado realizado en Dinamarca, se dio seguimiento a 32 pacientes de c\u00e1ncer de mama durante 18 meses.[ [15](#cit/section_5.15)] La enfermedad de estos pacientes se hab\u00eda diseminado a los [ganglios linf\u00e1ticos axilares](/Common/PopUps/popDefinition.aspx?id=45607&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), y un n\u00famero sin notificar de pacientes presentaban [met\u00e1stasis](/Common/PopUps/popDefinition.aspx?id=46710&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) a distancia. Los pacientes recibieron suplementos [antioxidantes](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (vitamina C, vitamina E y [betacaroteno](/Common/PopUps/popDefinition.aspx?id=45328&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)), otras [vitaminas](/Common/PopUps/popDefinition.aspx?id=44744&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y [oligoelementos](/Common/PopUps/popDefinition.aspx?id=45787&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [\u00e1cidos grasos](/Common/PopUps/popDefinition.aspx?id=45689&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) esenciales y coenzima Q10 (dosis de 90 mg/d\u00eda), adem\u00e1s del [tratamiento est\u00e1ndar](/Common/PopUps/popDefinition.aspx?id=44930&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) ( [cirug\u00eda](/Common/PopUps/popDefinition.aspx?id=45570&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), radioterapia y quimioterapia, con [tamoxifeno](/Common/PopUps/popDefinition.aspx?id=509341&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) o sin este). Se cit\u00f3 a los pacientes cada 3 meses para [controlar](/Common/PopUps/popDefinition.aspx?id=454803&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) el estado de la enfermedad ( [progresiva](/Common/PopUps/popDefinition.aspx?id=45850&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) o [recidivante](/Common/PopUps/popDefinition.aspx?id=45861&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)) y, en caso de sospecha de una recidiva, se los someti\u00f3 a [mamograf\u00eda](/Common/PopUps/popDefinition.aspx?id=45996&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [gammagraf\u00eda \u00f3sea](/Common/PopUps/popDefinition.aspx?id=46499&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [radiograf\u00eda](/Common/PopUps/popDefinition.aspx?id=45944&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) o [biopsia](/Common/PopUps/popDefinition.aspx?id=45164&version=healthprofessional&language=Spanish&dictionary=Cancer.gov). La [tasa de supervivencia](/Common/PopUps/popDefinition.aspx?id=44301&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) durante el per\u00edodo del estudio fue del 100 % (se esperaban 4 defunciones). Se notific\u00f3 que 6 pacientes presentaron algunos indicios de [remisi\u00f3n](/Common/PopUps/popDefinition.aspx?id=45867&version=healthprofessional&language=Spanish&dictionary=Cancer.gov); sin embargo, se proporcionaron datos cl\u00ednicos incompletos y la informaci\u00f3n indicativa de remisi\u00f3n solo estuvo disponible para 3 de los 6 pacientes. Ninguno de los 6 pacientes present\u00f3 hallazgos sugestivos de otras met\u00e1stasis. Se notific\u00f3 disminuci\u00f3n del uso de analg\u00e9sicos, mejora de la [calidad de vida](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y ausencia de perdida de peso en los 32 pacientes. No se especific\u00f3 si el uso de analg\u00e9sicos y la calidad de vida se midieron de forma objetiva (por ejemplo, a partir de registros de farmacia y cuestionarios validados, respectivamente) o subjetiva (autoinformes de los pacientes).\nEn un estudio de\n[seguimiento](/Common/PopUps/popDefinition.aspx?id=44671&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), 1 de los 6 pacientes con remisi\u00f3n notificada y otro paciente nuevo se trataron durante varios meses con dosis m\u00e1s altas de coenzima Q10 (390 mg/d\u00eda y 300 mg/d\u00eda, respectivamente).[ [16](#cit/section_5.16)] La extirpaci\u00f3n quir\u00fargica del tumor [primario](/Common/PopUps/popDefinition.aspx?id=45847&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de mama en ambos pacientes hab\u00eda sido incompleta. Despu\u00e9s de 3 a 4 meses de recibir dosis altas de coenzima Q10 ambos pacientes presentaron una [regresi\u00f3n](/Common/PopUps/popDefinition.aspx?id=46039&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) completa de los tumores de mama [residuales](/Common/PopUps/popDefinition.aspx?id=45869&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (evaluada mediante examen cl\u00ednico y mamograf\u00eda). Cabe se\u00f1alar que, en el estudio de seguimiento, se utiliz\u00f3 un identificador diferente para el paciente que hab\u00eda participado en el estudio original. Por lo tanto, es imposible determinar cu\u00e1l de los 6 pacientes con una remisi\u00f3n notificada particip\u00f3 en el estudio de seguimiento. En el informe del estudio de seguimiento, los investigadores notificaron que los 32 pacientes del estudio original segu\u00edan vivos a los 24 meses de [observaci\u00f3n](/Common/PopUps/popDefinition.aspx?id=45981&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), aunque se esperaban 6 defunciones.[ [16](#cit/section_5.16)]\nEn otro informe de los mismos\n[investigadores](/Common/PopUps/popDefinition.aspx?id=44685&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), se notific\u00f3 que 3 pacientes de c\u00e1ncer de mama que recibieron dosis altas de coenzima Q10(390 mg/d\u00eda) se siguieron durante 3 a 5 a\u00f1os.[ [11](#cit/section_5.11)] Un paciente tuvo una [remisi\u00f3n completa](/Common/PopUps/popDefinition.aspx?id=45651&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de las [met\u00e1stasis hep\u00e1ticas](/Common/PopUps/popDefinition.aspx?id=45316&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (determinada por examen cl\u00ednico y [ecograf\u00eda](/Common/PopUps/popDefinition.aspx?id=45557&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)), otro tuvo una remisi\u00f3n de un tumor que se hab\u00eda diseminado a la [pared tor\u00e1cica](/Common/PopUps/popDefinition.aspx?id=44996&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (determinada por examen cl\u00ednico y [radiograf\u00eda de t\u00f3rax](/Common/PopUps/popDefinition.aspx?id=304687&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)) y el tercer paciente no present\u00f3 hallazgos [microsc\u00f3picos](/Common/PopUps/popDefinition.aspx?id=44608&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de restos tumorales despu\u00e9s de una [mastectom\u00eda](/Common/PopUps/popDefinition.aspx?id=45777&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (determinados por biopsia del lecho tumoral).\nLos 3 estudios en seres humanos antes mencionados [\n[11](#cit/section_5.11), [15](#cit/section_5.15), [16](#cit/section_5.16)] tuvieron importantes defectos de dise\u00f1o que podr\u00edan haber influido en sus resultados. Las defectos del estudio fueron la ausencia de un grupo de control (es decir, todos los pacientes recibieron coenzima Q10), un posible [sesgo de selecci\u00f3n](/Common/PopUps/popDefinition.aspx?id=44087&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en las investigaciones de seguimiento y m\u00faltiples variables de confusi\u00f3n (es decir, los pacientes recibieron diferentes suplementos adem\u00e1s de la coenzima Q10 y se les administr\u00f3 tratamiento est\u00e1ndar mientras recib\u00edan los suplementos de coenzima Q10o justo antes de recibirlos). En consecuencia, no es posible determinar si alguno de los resultados beneficiosos se relacion\u00f3 en forma directa con la terapia de coenzima Q10.\nTambi\u00e9n se dispone de\n[informes anecd\u00f3ticos](/Common/PopUps/popDefinition.aspx?id=43995&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en la bibliograf\u00eda cient\u00edfica revisada por expertos donde se indica que la coenzima Q10 prolonga la supervivencia de pacientes con c\u00e1ncer de [p\u00e1ncreas](/Common/PopUps/popDefinition.aspx?id=44074&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [pulm\u00f3n](/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [recto](/Common/PopUps/popDefinition.aspx?id=44083&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [laringe](/Common/PopUps/popDefinition.aspx?id=46317&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), [colon](/Common/PopUps/popDefinition.aspx?id=46462&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y [pr\u00f3stata](/Common/PopUps/popDefinition.aspx?id=46539&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [6](#cit/section_5.6)] Los pacientes descritos en estos informes tambi\u00e9n recibieron otras terapia adem\u00e1s de la coenzima Q10, incluso quimioterapia, radioterapia y cirug\u00eda.\nEnsayos cl\u00ednicos en curso\nRealizar una\n[b\u00fasqueda avanzada](https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search) en ingl\u00e9s de los ensayos cl\u00ednicos sobre c\u00e1ncer auspiciados por el NCI que ahora aceptan pacientes. La b\u00fasqueda se puede simplificar por ubicaci\u00f3n del ensayo, tipo de tratamiento, nombre del f\u00e1rmaco y otros criterios. Tambi\u00e9n se dispone de [informaci\u00f3n general](https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos) sobre los ensayos cl\u00ednicos.\nBibliograf\u00eda\n- Ambrosone CB, Zirpoli GR, Hutson AD, et al.: Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol 38 (8): 804-814, 2020.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31855498&dopt=Abstract)\n- Cortes EP, Gupta M, Chou C, et al.: Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 62 (6): 887-91, 1978.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=667863&dopt=Abstract)\n- Usui T, Ishikura H, Izumi Y, et al.: Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q10. Toxicol Lett 12 (1): 75-82, 1982.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7112605&dopt=Abstract)\n- Iwamoto Y, Hansen IL, Porter TH, et al.: Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity. Biochem Biophys Res Commun 58 (3): 633-8, 1974.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4152017&dopt=Abstract)\n- Folkers K, Wolaniuk A: Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res 11 (8): 539-45, 1985.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract)\n- Folkers K, Brown R, Judy WV, et al.: Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 192 (1): 241-5, 1993.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract)\n- Iarussi D, Auricchio U, Agretto A, et al.: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 15 (Suppl): s207-12, 1994.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752832&dopt=Abstract)\n- Lesser GJ, Case D, Stark N, et al.: A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol 11 (1): 31-42, 2013.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22682875&dopt=Abstract)\n- Iwase S, Kawaguchi T, Yotsumoto D, et al.: Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01). Support Care Cancer 24 (2): 637-646, 2016.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26105516&dopt=Abstract)\n- Folkers K, Osterborg A, Nylander M, et al.: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234 (2): 296-9, 1997.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract)\n- Lockwood K, Moesgaard S, Yamamoto T, et al.: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212 (1): 172-7, 1995.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract)\n- Folkers K: Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 224 (2): 358-61, 1996.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract)\n- Ren S, Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48: 147-71, 1997.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract)\n- Shidal C, Yoon HS, Zheng W, et al.: Prospective study of plasma levels of coenzyme Q10 and lung cancer risk in a low-income population in the Southeastern United States. Cancer Med 10 (4): 1439-1447, 2021.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33547884&dopt=Abstract)\n- Lockwood K, Moesgaard S, Hanioka T, et al.: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15 (Suppl): s231-40, 1994.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract)\n- Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 199 (3): 1504-8, 1994.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7908519&dopt=Abstract)\nEfectos adversos\nNo se ha notificado\n[toxicidad](/Common/PopUps/popDefinition.aspx?id=43986&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) grave relacionada con el uso de [coenzima](/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) Q10 .[ [1](#cit/section_6.1)- [4](#cit/section_6.4)] Las [dosis](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de 100 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)/d\u00eda o m\u00e1s causaron [insomnio](/Common/PopUps/popDefinition.aspx?id=44043&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) leve en algunas personas. Se detect\u00f3 un aumento de las [enzimas](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) [hep\u00e1ticas](/Common/PopUps/popDefinition.aspx?id=46312&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en pacientes que tomaron dosis de 300 mg/d\u00eda durante per\u00edodos largos, pero no se inform\u00f3 de efectos t\u00f3xicos en el h\u00edgado.[ [1](#cit/section_6.1)] Los investigadores de un [estudio](/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) [cardiovascular](/Common/PopUps/popDefinition.aspx?id=44005&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) notificaron que la coenzima Q10 caus\u00f3 erupciones cut\u00e1neas, [n\u00e1useas](/Common/PopUps/popDefinition.aspx?id=390302&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y dolor [epig\u00e1strico](/Common/PopUps/popDefinition.aspx?id=44027&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (parte superior del [abdomen](/Common/PopUps/popDefinition.aspx?id=46684&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)) que exigieron la salida del estudio de un peque\u00f1o n\u00famero de pacientes.[ [5](#cit/section_6.5)] Otros [efectos secundarios](/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) notificados incluyeron mareos, [fotofobia](/Common/PopUps/popDefinition.aspx?id=44077&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (sensibilidad visual anormal a la luz), irritabilidad,[ [5](#cit/section_6.5)] dolor de cabeza, ardor de est\u00f3mago y [fatiga](/Common/PopUps/popDefinition.aspx?id=321374&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [6](#cit/section_6.6)]\nEn un estudio\n[prospectivo](/Common/PopUps/popDefinition.aspx?id=44079&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) donde se analiz\u00f3 la relaci\u00f3n entre el uso de suplementos y los desenlaces del [c\u00e1ncer de mama](/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) ( [SWOG S0221](/clinicaltrials/NCT00070564)), el uso de cualquier tipo de suplemento [antioxidante](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) antes del tratamiento o durante el mismo, incluso la coenzima Q10, la [vitamina A](/Common/PopUps/popDefinition.aspx?id=45248&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), la [vitamina C](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), la [vitamina E](/Common/PopUps/popDefinition.aspx?id=45023&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y los carotenoides, se relacion\u00f3 con una tendencia que indic\u00f3 un mayor riesgo de [recidiva](/Common/PopUps/popDefinition.aspx?id=45861&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (cociente de riesgos instant\u00e1neos ajustado, 1,41; intervalo de confianza, 0,98\u20132,04, P = 0,06).[ [7](#cit/section_6.7)]\nCiertos f\u00e1rmacos para disminuir los\n[l\u00edpidos](/Common/PopUps/popDefinition.aspx?id=46068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), como las [estatinas](/Common/PopUps/popDefinition.aspx?id=390255&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) (lovastatina, [pravastatina](/Common/PopUps/popDefinition.aspx?id=618548&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) y simvastatina) y el gemfibrozilo, as\u00ed como los f\u00e1rmacos de administraci\u00f3n [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) que reducen el az\u00facar en la [sangre](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), como la gliburida (glibenclamida) y la tolazamida, producen una disminuci\u00f3n de las concentraciones [s\u00e9ricas](/Common/PopUps/popDefinition.aspx?id=44088&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) de la coenzima Q10y reducen los efectos de la coenzima Q10 como un [suplemento](/Common/PopUps/popDefinition.aspx?id=45916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [1](#cit/section_6.1), [8](#cit/section_6.8)- [10](#cit/section_6.10)] Los betabloqueantes (f\u00e1rmacos que reducen la frecuencia card\u00edaca y disminuyen la [presi\u00f3n arterial](/Common/PopUps/popDefinition.aspx?id=462668&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)) inhiben las reacciones enzim\u00e1ticas que dependen de la coenzima Q10. La fuerza contr\u00e1ctil del coraz\u00f3n en pacientes con [presi\u00f3n arterial alta](/Common/PopUps/popDefinition.aspx?id=458091&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) aumenta con la administraci\u00f3n de la coenzima Q10.[ [1](#cit/section_6.1)] La coenzima Q10 reduce la respuesta del cuerpo al [anticoagulante](/Common/PopUps/popDefinition.aspx?id=46082&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) [warfarina](/Common/PopUps/popDefinition.aspx?id=45249&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).[ [10](#cit/section_6.10)] Por \u00faltimo, la coenzima Q10 reduce las necesidades de [insulina](/Common/PopUps/popDefinition.aspx?id=46187&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) en personas con [diabetes](/Common/PopUps/popDefinition.aspx?id=44911&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).\nBibliograf\u00eda\n- Pepping J: Coenzyme Q10. Am J Health Syst Pharm 56 (6): 519-21, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract)\n- Overvad K, Diamant B, Holm L, et al.: Coenzyme Q10 in health and disease. Eur J Clin Nutr 53 (10): 764-70, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract)\n- Hodges S, Hertz N, Lockwood K, et al.: CoQ10: could it have a role in cancer management? Biofactors 9 (2-4): 365-70, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416054&dopt=Abstract)\n- Heller JH: Disease, the host defense, and Q-10. Perspect Biol Med 16 (2): 181-7, 1973 Winter.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4689357&dopt=Abstract)\n- Baggio E, Gandini R, Plancher AC, et al.: Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 15 (Suppl): s287-94, 1994.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752841&dopt=Abstract)\n- Feigin A, Kieburtz K, Como P, et al.: Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 11 (3): 321-3, 1996.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8723151&dopt=Abstract)\n- Ambrosone CB, Zirpoli GR, Hutson AD, et al.: Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol 38 (8): 804-814, 2020.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31855498&dopt=Abstract)\n- Kaikkonen J, Nyyss\u00f6nen K, Tuomainen TP, et al.: Determinants of plasma coenzyme Q10 in humans. FEBS Lett 443 (2): 163-6, 1999.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9989597&dopt=Abstract)\n- Thibault A, Samid D, Tompkins AC, et al.: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2 (3): 483-91, 1996.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9816194&dopt=Abstract)\n- Coenzyme Q10. In: Jellin JM, Hitchens K, eds.: Natural Medicines Comprehensive Database. Therapeutic Research Faculty, 1999, pp 241-42.\nResumen de la evidencia sobre la coenzima Q10\nCon el fin de ayudar a los lectores a evaluar los resultados de los\n[estudios](/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) con seres humanos sobre las terapias integrales, alternativas y complementarias del [c\u00e1ncer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), se informa, siempre que sea posible, acerca de la solidez de la evidencia (es decir, los [niveles de evidencia cient\u00edfica](/Common/PopUps/popDefinition.aspx?id=446533&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)) de cada tipo de tratamiento. Para poder realizar un [an\u00e1lisis](/Common/PopUps/popDefinition.aspx?id=390238&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) del nivel de evidencia, el estudio debe cumplir los siguientes requisitos:\n- Estar publicado en una\n[revista cient\u00edfica con revisi\u00f3n externa](/Common/PopUps/popDefinition.aspx?id=537399&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).\n- Informar sobre los\n[desenlaces](/Common/PopUps/popDefinition.aspx?id=467853&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) [terap\u00e9uticos](/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)o resultados como la [respuesta](/Common/PopUps/popDefinition.aspx?id=44085&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)del [tumor](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=Spanish&dictionary=Cancer.gov), una mejora de la supervivencia o una mejora cuantificable de la [calidad de vida](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=Spanish&dictionary=Cancer.gov).\n- Describir los hallazgos cl\u00ednicos con detalles suficientes como para poder llevar a cabo una evaluaci\u00f3n relevante.\nCon el objeto de clasificar los estudios con seres humanos, se les asignan puntajes de niveles de evidencia cient\u00edfica por separado, seg\u00fan la solidez estad\u00edstica del dise\u00f1o del estudio y la solidez cient\u00edfica de los resultados del tratamiento (es decir, los\n[criterios de valoraci\u00f3n](/Common/PopUps/popDefinition.aspx?id=346519&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)) analizados. Los dos puntajes resultantes se combinan para calcular el puntaje total. En el cuadro que se presenta a continuaci\u00f3n, figuran los puntajes de los niveles de evidencia de los estudios con seres humanos citados en este sumario. Para obtener una explicaci\u00f3n de los puntajes e informaci\u00f3n adicional sobre el an\u00e1lisis de los niveles de evidencia cient\u00edfica de los estudios de c\u00e1ncer, consultar [Niveles de evidencia de los estudios sobre las terapias integrales, alternativas y complementarias en seres humanos con c\u00e1ncer](/espanol/publicaciones/pdq/niveles-de-evidencia/cam).\n|N\u00famero de la referencia||Solidez estad\u00edstica del dise\u00f1o de estudio||Solidez de los criterios de valoraci\u00f3n analizados||Puntaje combinado|\n|\n[\n|[Series de casos no consecutivos](/Common/PopUps/popDefinition.aspx?id=44575&version=healthprofessional&language=Spanish&dictionary=Cancer.gov)\nBibliograf\u00eda\n- Lockwood K, Moesgaard S, Hanioka T, et al.: Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15 (Suppl): s231-40, 1994.\n[[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract)\nModificaciones a este resumen (08/18/2022)\nLos res\u00famenes del\n[PDQ](/Common/PopUps/popDefinition.aspx?id=44271&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) con informaci\u00f3n sobre el [c\u00e1ncer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov) se revisan con regularidad y se actualizan a medida que se obtiene nueva informaci\u00f3n. Esta secci\u00f3n describe los cambios m\u00e1s recientes introducidos en este resumen a partir de la fecha arriba indicada.\nSe incorporaron cambios editoriales en este sumario.\nEl\n[Consejo editorial del PDQ\u00ae sobre las terapias integrales, alternativas y complementarias](https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa) es responsable de la redacci\u00f3n y actualizaci\u00f3n de este resumen y mantiene independencia editorial respecto del NCI. El resumen refleja una revisi\u00f3n independiente de la bibliograf\u00eda m\u00e9dica y no representa las pol\u00edticas del NCI ni de los NIH. Para obtener m\u00e1s informaci\u00f3n sobre las pol\u00edticas relativas a los res\u00famenes y la funci\u00f3n de los consejos editoriales del PDQ responsables de su actualizaci\u00f3n, consultar [Informaci\u00f3n sobre este sumario del PDQ](/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq#_AboutThis_1) e [Informaci\u00f3n del PDQ\u00ae sobre el c\u00e1ncer dirigida a profesionales de la salud](https://www.cancer.gov/espanol/publicaciones/pdq).\nInformaci\u00f3n sobre este sumario del PDQ\nProp\u00f3sito de este sumario\nEste sumario del PDQ con informaci\u00f3n sobre el c\u00e1ncer para profesionales de la salud proporciona informaci\u00f3n integral revisada por expertos y fundamentada en evidencia cient\u00edfica sobre el uso de la coenzima Q10 como tratamiento para las personas con c\u00e1ncer. El prop\u00f3sito es servir como fuente de informaci\u00f3n y ayuda para los m\u00e9dicos que atienden a pacientes de c\u00e1ncer. No ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci\u00f3n sanitaria.\nRevisores y actualizaciones\nEl\n[Consejo editorial del PDQ\u00ae sobre las terapias integrales, alternativas y complementarias](https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa), cuya funci\u00f3n editorial es independiente del Instituto Nacional del C\u00e1ncer (NCI), revisa con regularidad este sumario y, en caso necesario, lo actualiza. Este sumario refleja una revisi\u00f3n bibliogr\u00e1fica independiente y no constituye una declaraci\u00f3n de la pol\u00edtica del Instituto Nacional del C\u00e1ncer ni de los Institutos Nacionales de la Salud (NIH).\nCada mes, los miembros de este Consejo examinan art\u00edculos publicados recientemente para determinar si se deben:\n- tratar en una reuni\u00f3n,\n- citar textualmente, o\n- sustituir o actualizar, si ya se citaron con anterioridad.\nLos cambios en los sumarios se deciden mediante consenso, una vez que los integrantes del Consejo eval\u00faan la solidez de la evidencia cient\u00edfica de los art\u00edculos publicados y determinan la forma en que se incorporar\u00e1n al sumario.\nCualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el\n[formulario de comunicaci\u00f3n](https://www.cancer.gov/espanol/contactenos/correo-electronico) en Cancer.gov/espanol del NCI. No se comunique con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios. Los miembros del Consejo no responder\u00e1n a preguntas del p\u00fablico.\nNiveles de evidencia cient\u00edfica\nEn algunas referencias bibliogr\u00e1ficas de este sumario se indica el nivel de evidencia cient\u00edfica. El prop\u00f3sito de estas designaciones es ayudar al lector a evaluar la solidez de la evidencia cient\u00edfica que respalda el uso de ciertas intervenciones o abordajes. El Consejo editorial del PDQ\u00ae sobre las terapias integrales, alternativas y complementarias emplea un\n[sistema de jerarquizaci\u00f3n formal](/espanol/publicaciones/pdq/niveles-de-evidencia/cam) para establecer las designaciones del nivel de evidencia cient\u00edfica.\nPermisos para el uso de este sumario\nPDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto de los documentos del PDQ. Sin embargo, no se podr\u00e1 identificar como un sumario de informaci\u00f3n sobre c\u00e1ncer del PDQ del NCI, salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir\u00e1 que un autor escriba una oraci\u00f3n como \u201cEn el sumario del PDQ del NCI de informaci\u00f3n sobre la prevenci\u00f3n del c\u00e1ncer de mama se describen, de manera concisa, los siguientes riesgos: [incluir fragmento del sumario]\u201d.\nSe sugiere citar la referencia bibliogr\u00e1fica de este sumario del PDQ de la siguiente forma:\nPDQ\u00ae . PDQ Coenzima Q10. Bethesda, MD: National Cancer Institute. Actualizaci\u00f3n: <MM/DD/YYYY>. Disponible en:\n[https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq](https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq). Fecha de acceso: <MM/DD/YYYY>.\nLas im\u00e1genes en este sumario se reproducen con el permiso del autor, el artista o la editorial para uso exclusivo en los sumarios del PDQ. La utilizaci\u00f3n de las im\u00e1genes fuera del PDQ requiere la autorizaci\u00f3n del propietario, que el Instituto Nacional del C\u00e1ncer no puede otorgar. Para obtener m\u00e1s informaci\u00f3n sobre el uso de las ilustraciones de este sumario o de otras im\u00e1genes relacionadas con el c\u00e1ncer, consultar\n[Visuals Online](https://visualsonline.cancer.gov/), una colecci\u00f3n de m\u00e1s de 2000 im\u00e1genes cient\u00edficas.\nCl\u00e1usula sobre el descargo de responsabilidad\nLa informaci\u00f3n en estos sumarios no se debe utilizar como base para determinar reembolsos por parte de las aseguradoras. Para obtener m\u00e1s informaci\u00f3n sobre la cobertura de seguros, consultar la p\u00e1gina\n[Manejo de la atenci\u00f3n del c\u00e1ncer](https://www.cancer.gov/espanol/cancer/manejo-del-cancer) disponible en Cancer.gov/espanol.\nPara obtener m\u00e1s informaci\u00f3n\nEn Cancer.gov/espanol, se ofrece m\u00e1s informaci\u00f3n sobre c\u00f3mo comunicarse o recibir ayuda en\n[\u00bfEn qu\u00e9 podemos ayudarle?](https://www.cancer.gov/espanol/contactenos).\nTambi\u00e9n se puede enviar un mensaje de correo electr\u00f3nico mediante este [formulario](https://www.cancer.gov/espanol/contactenos/correo-electronico).", "language": null, "image": null, "pagetype": "Website", "links": ["#main-content", "/about-cancer/treatment/cam/hp/coenzyme-q10-pdq", "/espanol", "/espanol/cancer", "/espanol/tipos", "/espanol/investigacion", "/espanol/subvenciones-capacitacion", "/espanol/noticias", "/espanol/instituto", "/espanol", "/espanol/cancer", "/espanol/cancer/tratamiento", "/espanol/cancer/tratamiento/mca", "/espanol/cancer/tratamiento/mca/pro", "mailto:?subject=Informaci\u00f3n del portal de Internet del Instituto Nacional del C\u00e1ncer &body=Encontr\u00e9 esta informaci\u00f3n en cancer.gov/espanol y quiero compartirla contigo: https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq %0D%0A%0D%0A El sitio web del Instituto Nacional del C\u00e1ncer (NCI), www.cancer.gov/espanol, provee informaci\u00f3n precisa, al d\u00eda y completa de la dependencia principal del gobierno de EE. UU. sobre investigaci\u00f3n de c\u00e1ncer. Si tiene preguntas o necesita m\u00e1s informaci\u00f3n, le invitamos a que se comunique en espa\u00f1ol con el servicio de mensajer\u00eda instant\u00e1nea LiveHelp del NCI en https://livehelp-es.cancer.gov, o llame el Centro de Contacto del NCI al 1-800-422-6237 (1-800-4-CANCER) sin cargos en los Estados Unidos.", "/espanol/cancer/tratamiento", "/espanol/cancer/tratamiento/tipos", "/espanol/cancer/tratamiento/efectos-secundarios", "/espanol/cancer/tratamiento/estudios-clinicos", "/espanol/cancer/tratamiento/medicamentos", "/espanol/cancer/tratamiento/mca", "/espanol/cancer/tratamiento/mca/paciente", "/espanol/cancer/tratamiento/mca/pro", "/espanol/cancer/tratamiento/preguntas", "/espanol/cancer/tratamiento/investigacion", "#_3", "#_9", "#_23", "#_27", "#_30", "#_43", "#_47", "#_52", "#_AboutThis_1", "/espanol/cancer/tratamiento/mca/paciente/coenzima-q10-pdq", "/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45858&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "https://www.cancer.gov/publications/dictionaries/cancer-terms/", "/Common/PopUps/popDefinition.aspx?id=44271&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45065&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46092&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=43993&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=43992&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44071&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44008&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.1", "#cit/section_2.4", "/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44026&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.1", "#cit/section_2.2", "#cit/section_2.4", "#cit/section_2.8", "/Common/PopUps/popDefinition.aspx?id=44030&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44393&version=healthprofessional&language=Spanish&dictionary=genetic", "/Common/PopUps/popDefinition.aspx?id=46068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44072&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.9", "#cit/section_2.10", "/Common/PopUps/popDefinition.aspx?id=46683&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.11", "/Common/PopUps/popDefinition.aspx?id=46312&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46325&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46254&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.11", "#cit/section_2.11", "#cit/section_2.12", "/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=306521&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44214&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.2", "#cit/section_2.4", "#cit/section_2.13", "#cit/section_2.14", "/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44005&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.2", "#cit/section_2.4", "#cit/section_2.15", "/Common/PopUps/popDefinition.aspx?id=44004&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.3", "#cit/section_2.16", "#cit/section_2.18", "/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.19", "#cit/section_2.20", "/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.21", "#cit/section_2.27", "/Common/PopUps/popDefinition.aspx?id=285968&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45587&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.17", "#cit/section_2.20", "#cit/section_2.28", "#cit/section_2.33", "/Common/PopUps/popDefinition.aspx?id=44919&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44572&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45733&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46631&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.12", "#cit/section_2.34", "/Common/PopUps/popDefinition.aspx?id=45152&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44124&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44009&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.12", "#cit/section_2.34", "/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=454785&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=439419&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44168&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44678&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46339&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44048&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45914&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=455334&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45738&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_2.4", "#cit/section_2.2", "#cit/section_2.4", "/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241706&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8760864&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9250020&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7599208&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9636673&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9266509&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241707&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9760013&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752841&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=667863&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752832&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7163631&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10079467&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5478631&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1673841&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=101414&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416052&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7908519&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416054&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=653103&dopt=Abstract", "/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.1", "#cit/section_3.2", "/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=321364&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.2", "#cit/section_3.4", "/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44167&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45849&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.5", "/Common/PopUps/popDefinition.aspx?id=45771&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45795&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45368&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46539&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46254&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46462&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46325&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=257519&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.2", "#cit/section_3.6", "#cit/section_3.7", "/Common/PopUps/popDefinition.aspx?id=46683&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45772&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.8", "#cit/section_3.12", "#cit/section_3.8", "/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.2", "/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44918&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.13", "/Common/PopUps/popDefinition.aspx?id=44054&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44928&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45765&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.13", "#cit/section_3.14", "/Common/PopUps/popDefinition.aspx?id=45364&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.15", "#cit/section_3.17", "/Common/PopUps/popDefinition.aspx?id=45725&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.18", "#cit/section_3.20", "/Common/PopUps/popDefinition.aspx?id=46092&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44594&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.21", "#cit/section_3.22", "/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.23", "#cit/section_3.27", "/Common/PopUps/popDefinition.aspx?id=43991&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.1", "#cit/section_3.25", "#cit/section_3.28", "/Common/PopUps/popDefinition.aspx?id=45611&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44953&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.6", "#cit/section_3.18", "/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq#_5", "#cit/section_3.1", "#cit/section_3.25", "#cit/section_3.27", "#cit/section_3.29", "#cit/section_3.32", "/Common/PopUps/popDefinition.aspx?id=46068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44030&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.1", "#cit/section_3.25", "#cit/section_3.27", "#cit/section_3.32", "/Common/PopUps/popDefinition.aspx?id=44393&version=healthprofessional&language=Spanish&dictionary=genetic", "/Common/PopUps/popDefinition.aspx?id=45065&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_3.11", "#cit/section_3.23", "#cit/section_3.30", "#cit/section_3.33", "#cit/section_3.36", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9760013&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5225398&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2538136&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9537635&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8751964&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10936586&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5478631&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=101414&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7163631&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1673841&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416052&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2957843&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3494139&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9636673&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9266509&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241706&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8241707&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8760864&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9250020&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7599208&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10601883&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10415430&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10415429&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8695238&dopt=Abstract", "/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44008&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45364&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44080&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_4.1", "#cit/section_4.2", "/Common/PopUps/popDefinition.aspx?id=45801&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44629&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_4.1", "#cit/section_4.4", "/Common/PopUps/popDefinition.aspx?id=44035&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_4.4", "#cit/section_4.5", "#cit/section_4.6", "#cit/section_4.5", "/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_4.7", "#cit/section_4.12", "/Common/PopUps/popDefinition.aspx?id=46339&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_4.13", "/Common/PopUps/popDefinition.aspx?id=44971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_4.14", "/Common/PopUps/popDefinition.aspx?id=45327&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44095&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44149&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44030&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44919&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_4.15", "#cit/section_4.16", "/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq#_5", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4346875&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4510283&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6078061&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=441512&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=928953&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=283424&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6928034&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8312867&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7112605&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7414051&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9821311&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4218125&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=653103&dopt=Abstract", "#_32_toc", "#_33_toc", "#_35_toc", "#_37_toc", "#_TrialSearch_30_sid_5_toc", "/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45961&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=346517&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=286105&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/clinicaltrials/NCT00070564", "/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45861&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.1", "/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45634&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44124&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44060&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.2", "#cit/section_5.4", "/Common/PopUps/popDefinition.aspx?id=45858&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.2", "#cit/section_5.5", "#cit/section_5.7", "#cit/section_5.7", "/Common/PopUps/popDefinition.aspx?id=44004&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44014&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=321374&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44840&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45587&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44764&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45023&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.8", "/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=446104&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=321377&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44149&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44167&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44163&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.9", "/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.10", "#cit/section_5.14", "/Common/PopUps/popDefinition.aspx?id=422394&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44950&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44066&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.15", "/Common/PopUps/popDefinition.aspx?id=45607&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46710&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45328&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44744&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45787&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45689&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44930&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45570&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=509341&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=454803&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45850&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45861&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45996&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46499&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45944&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45164&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44301&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45867&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44671&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.16", "/Common/PopUps/popDefinition.aspx?id=45847&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46039&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45869&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45981&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.16", "/Common/PopUps/popDefinition.aspx?id=44685&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.11", "/Common/PopUps/popDefinition.aspx?id=45651&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45316&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45557&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44996&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=304687&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44608&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45777&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.11", "#cit/section_5.15", "#cit/section_5.16", "/Common/PopUps/popDefinition.aspx?id=44087&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=43995&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44074&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44083&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46317&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46462&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46539&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_5.6", "https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search", "https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31855498&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=667863&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7112605&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4152017&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3836873&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8476426&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752832&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22682875&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26105516&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9177262&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7612003&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8702395&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9204686&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33547884&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7908519&dopt=Abstract", "/Common/PopUps/popDefinition.aspx?id=43986&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=346488&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_6.1", "#cit/section_6.4", "/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44043&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46312&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_6.1", "/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44005&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=390302&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44027&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46684&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_6.5", "/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44077&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_6.5", "/Common/PopUps/popDefinition.aspx?id=321374&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_6.6", "/Common/PopUps/popDefinition.aspx?id=44079&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/clinicaltrials/NCT00070564", "/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45248&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45023&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45861&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_6.7", "/Common/PopUps/popDefinition.aspx?id=46068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=390255&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=618548&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44088&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45916&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_6.1", "#cit/section_6.8", "#cit/section_6.10", "/Common/PopUps/popDefinition.aspx?id=462668&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=458091&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_6.1", "/Common/PopUps/popDefinition.aspx?id=46082&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45249&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "#cit/section_6.10", "/Common/PopUps/popDefinition.aspx?id=46187&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44911&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10192685&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10556981&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10416054&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4689357&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752841&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8723151&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31855498&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9989597&dopt=Abstract", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9816194&dopt=Abstract", "/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=446533&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=390238&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=537399&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=467853&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=44085&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=346519&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/espanol/publicaciones/pdq/niveles-de-evidencia/cam", "#cit/section_7.1", "/Common/PopUps/popDefinition.aspx?id=44575&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752835&dopt=Abstract", "/Common/PopUps/popDefinition.aspx?id=44271&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=Spanish&dictionary=Cancer.gov", "https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa", "/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq#_AboutThis_1", "https://www.cancer.gov/espanol/publicaciones/pdq", "https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa", "https://www.cancer.gov/espanol/contactenos/correo-electronico", "/espanol/publicaciones/pdq/niveles-de-evidencia/cam", "https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq", "https://visualsonline.cancer.gov/", "https://www.cancer.gov/espanol/cancer/manejo-del-cancer", "https://www.cancer.gov/espanol/contactenos", "https://www.cancer.gov/espanol/contactenos/correo-electronico", "/espanol/politicas/derechos-de-autor-y-uso", "/espanol/sindicacion", "mailto:?subject=Informaci\u00f3n del portal de Internet del Instituto Nacional del C\u00e1ncer &body=Encontr\u00e9 esta informaci\u00f3n en cancer.gov/espanol y quiero compartirla contigo: https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/coenzima-q10-pdq %0D%0A%0D%0A El sitio web del Instituto Nacional del C\u00e1ncer (NCI), www.cancer.gov/espanol, provee informaci\u00f3n precisa, al d\u00eda y completa de la dependencia principal del gobierno de EE. UU. sobre investigaci\u00f3n de c\u00e1ncer. Si tiene preguntas o necesita m\u00e1s informaci\u00f3n, le invitamos a que se comunique en espa\u00f1ol con el servicio de mensajer\u00eda instant\u00e1nea LiveHelp del NCI en https://livehelp-es.cancer.gov, o llame el Centro de Contacto del NCI al 1-800-422-6237 (1-800-4-CANCER) sin cargos en los Estados Unidos.", "#top", "/espanol/acerca-sitio", "/", "/espanol/politicas/derechos-de-autor-y-uso", "/espanol/redes-sociales", "/espanol/contactenos", "/espanol/publicaciones", "/espanol/publicaciones/diccionarios/diccionario-cancer", "/espanol/politicas/accesibilidad", "/espanol/politicas/foia", "/espanol/politicas/confidencialidad-seguridad", "/espanol/politicas/exoneracion", "https://www.hhs.gov/es/vulnerability-disclosure-policy/index.html", "https://livehelp-es.cancer.gov/", "tel:1-800-422-6237", "mailto:NCIinfo@nih.gov", "https://www.facebook.com/cancer.govEspanol", "https://twitter.com/NCIespanol", "https://www.youtube.com/playlist?list=PLYKy4VbxNln7Cy6K2hZvwHLIZAElio5ai", "https://www.hhs.gov/", "https://salud.nih.gov/", "https://www.cancer.gov/espanol", "https://www.usa.gov/espanol/"]}